Allergan PLC (AGN)

216.52
1.70 0.81
NYSE : Health Care
Prev Close 214.78
Open 216.50
Day Low/High 214.70 / 219.13
52 Wk Low/High 184.50 / 301.98
Volume 985.05K
Avg Volume 5.27M
Exchange NYSE
Shares Outstanding 374.95M
Market Cap 81.04B
EPS 10.00
P/E Ratio 15.82
Div & Yield 2.80 (1.30%)

Latest News

Allergan And Gedeon Richter Announce Positive Phase III Results For Ulipristal Acetate 5 And 10 Mg In The Treatment Of Uterine Fibroids

Allergan And Gedeon Richter Announce Positive Phase III Results For Ulipristal Acetate 5 And 10 Mg In The Treatment Of Uterine Fibroids

- First oral therapy to demonstrate efficacy and safety for uterine fibroids in two U.S. pivotal studies -

Allergan, Citigroup, Apple: Doug Kass' Views

Allergan, Citigroup, Apple: Doug Kass' Views

Doug Kass shares his thoughts on how he had one of his best days in recent memory, and warns you not to look in the rear view mirror.

Allergan, Schlumberger, IBM: Doug Kass' Views

Allergan, Schlumberger, IBM: Doug Kass' Views

Doug Kass shares his thoughts on animal spirits, and discusses his astonishment at some rising optimism.

Jobless Claims and Trimming GLD: Best of Kass

Jobless Claims and Trimming GLD: Best of Kass

In highlights from this week's trading diary and posts, Kass tells us about how he's selling some Allergan shares and how he feels about the jobless claims.

Weekly Roundup

Trump's press conference puts a charge into an otherwise flat week. We add a position to the portfolio.

Trump's Remarks Show Why Pharma Sector Is 'Barely Investable': More Squawk From Jim Cramer

Trump's Remarks Show Why Pharma Sector Is 'Barely Investable': More Squawk From Jim Cramer

TheStreet's Jim Cramer weighs in on Donald Trump's comments regarding biotech and pharmaceuticals during his first press conference since the election.

Jim Cramer: How to Play Health Care Stocks Ahead of the Inaguration

Jim Cramer: How to Play Health Care Stocks Ahead of the Inaguration

Is the renewed Obamacare debate an opportunity to buy health care stocks?

Biotech Just Got Trumped

Biotech Just Got Trumped

But the 3% drop in the sector yesterday is clearly an overreaction to Trump's comments.

Allergan To Report Fourth Quarter And Full Year 2016 Earnings And Host Conference Call And Webcast

Allergan To Report Fourth Quarter And Full Year 2016 Earnings And Host Conference Call And Webcast

-- Company to Provide Full-Year 2017 Guidance --

Closing Bell: Volkswagen Secures Plea Deal; Trump Triggers Biotech Selloff

Closing Bell: Volkswagen Secures Plea Deal; Trump Triggers Biotech Selloff

Wall Street secured gains again by late afternoon Wednesday in unpredictable trading following President-elect Donald Trump's first press conference since July.

Cramer: Trump Doesn't Seem to Care About the Trump Rally

Cramer: Trump Doesn't Seem to Care About the Trump Rally

He's never really been a stock market guy anyway.

Allergan Shifts Strategy to Focus on Growth

Allergan Shifts Strategy to Focus on Growth

Drug company Allergan is set to shift its focus towards accretive M&A and away from the early-stage pipeline acquisitions that have disappointed investors.

Allergan Hints It Is Ready to Make a Splash for More Near-term Growth

Allergan Hints It Is Ready to Make a Splash for More Near-term Growth

CEO Brent Saunders plans to reward shareholders after striking a slew of R&D acquisitions in the latter half of 2016.

Celebrate One Debacle of a Merger With Another -- ICYMI

Celebrate One Debacle of a Merger With Another -- ICYMI

America Online and Time Warner see the 17-year anniversary of their combination come and go, as both companies are involved in separate merger dramas today.

Allergan Just Announced Two Significant Deals

Allergan Just Announced Two Significant Deals

Allergan is out with two important deals on Monday, just as the J.P. Morgan Healthcare Conference begins.

Allergan Continues Down 'Stepping Stone' Path With Two Deals

Allergan Continues Down 'Stepping Stone' Path With Two Deals

The pharmaceutical maker announced two deals Monday as a part of the JP Morgan health care conference.

Allergan Is a Blueprint for Gilead

Allergan Is a Blueprint for Gilead

At least, that's the case when it comes to a technical trade.

Allergan, Google, Oaktree Capital: Doug Kass' Views

Allergan, Google, Oaktree Capital: Doug Kass' Views

Doug Kass shares his thoughts on how January has a lot of nonsense, and reviews his investment troops.

Alphabet, Apple, Allergan: Doug Kass' Views

Alphabet, Apple, Allergan: Doug Kass' Views

Doug Kass shares his thoughts on the deepening of retail stocks' weakness and the Amazon Effect.

Craft a Strategy From Retail's Wreckage: Best of Kass

Craft a Strategy From Retail's Wreckage: Best of Kass

In highlights from this week's trading diary and posts, Kass tells us about how the market's optimism is misplaced and how to make a strategy from retail's wreckage.

Health Care, Banks Lead Game Strategy for Next Week: Cramer's 'Mad Money' Recap (Friday 1/6/17)

Health Care, Banks Lead Game Strategy for Next Week: Cramer's 'Mad Money' Recap (Friday 1/6/17)

Jim Cramer says he's focusing on health-care companies that will break news that moves stocks.

Weekly Roundup

Markets start 2017 on a high note, avoiding the pullbacks that have kicked off recent years.

Jim Cramer on the Problems With Buying Drug Stocks

Jim Cramer on the Problems With Buying Drug Stocks

Jim Cramer breaks down why it is so difficult to buy drug stocks right now.

Allergan Is a Bright Light on a Down Day

We believe AGN's latest guidance, coupled with increased transparency and the potential for accretive tuck-in M&A, sparks a more-optimistic outlook for the future.

Saunders Paints Realistic Outlook for Allergan in 2017

Saunders Paints Realistic Outlook for Allergan in 2017

Having fallen short of earnings expectations in its third quarter, Allergan says non-GAAP earnings per share should see double-digit growth in the year ahead.

What Pharma and Health Care Investors Should Watch for at JPM

What Pharma and Health Care Investors Should Watch for at JPM

The largest investor conference for the health care industry kicks off on Monday in San Francisco.

Allergan To Present At Goldman Sachs Healthcare CEOs Unscripted Conference And Provides Preliminary Comments On 2017 Outlook

Allergan To Present At Goldman Sachs Healthcare CEOs Unscripted Conference And Provides Preliminary Comments On 2017 Outlook

-- Company to Provide Full-Year GAAP and non-GAAP 2017 Financial Outlook on its Fourth Quarter 2016 Earnings Conference Call in February --